JP2010106028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010106028A5 JP2010106028A5 JP2009271611A JP2009271611A JP2010106028A5 JP 2010106028 A5 JP2010106028 A5 JP 2010106028A5 JP 2009271611 A JP2009271611 A JP 2009271611A JP 2009271611 A JP2009271611 A JP 2009271611A JP 2010106028 A5 JP2010106028 A5 JP 2010106028A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell surface
- kit
- binding region
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 176
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 112
- 102000006240 membrane receptors Human genes 0.000 claims description 112
- 230000027455 binding Effects 0.000 claims description 107
- 210000004027 cell Anatomy 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 52
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 47
- 102100034256 Mucin-1 Human genes 0.000 claims description 47
- 239000000523 sample Substances 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 23
- 230000011664 signaling Effects 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000000084 colloidal system Substances 0.000 claims description 15
- 230000002159 abnormal effect Effects 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 238000013188 needle biopsy Methods 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 230000001351 cycling effect Effects 0.000 claims description 4
- 238000001502 gel electrophoresis Methods 0.000 claims description 4
- 238000007898 magnetic cell sorting Methods 0.000 claims description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 35
- 230000003213 activating effect Effects 0.000 description 32
- 241000894007 species Species 0.000 description 31
- 239000003814 drug Substances 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000003993 interaction Effects 0.000 description 18
- 238000003776 cleavage reaction Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 230000007017 scission Effects 0.000 description 17
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 9
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 8
- 239000013610 patient sample Substances 0.000 description 7
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 description 6
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 6
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 6
- 239000013068 control sample Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 102000057860 human MUC1 Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- QVZVEEALAXDABJ-UHFFFAOYSA-N 4-(trifluoromethyl)-2-[5-(trifluoromethyl)-2,3-dihydrobenzimidazol-1-yl]phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1N1C2=CC=C(C(F)(F)F)C=C2NC1 QVZVEEALAXDABJ-UHFFFAOYSA-N 0.000 description 5
- 102000004899 14-3-3 Proteins Human genes 0.000 description 4
- CSJRQRBMUOOMFH-UHFFFAOYSA-N 3-butyl-2h-indazole Chemical compound C1=CC=C2C(CCCC)=NNC2=C1 CSJRQRBMUOOMFH-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108700020469 14-3-3 Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102000003908 Cathepsin D Human genes 0.000 description 3
- 108090000258 Cathepsin D Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 description 3
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 3
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 3
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 3
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 3
- 108010042362 beta-Lipotropin Proteins 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
Applications Claiming Priority (24)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25336100P | 2000-11-27 | 2000-11-27 | |
| US60/253,361 | 2000-11-27 | ||
| US25537000P | 2000-12-13 | 2000-12-13 | |
| US60/255,370 | 2000-12-13 | ||
| US25602700P | 2000-12-15 | 2000-12-15 | |
| US60/256,027 | 2000-12-15 | ||
| US25815700P | 2000-12-22 | 2000-12-22 | |
| US60/258,157 | 2000-12-22 | ||
| US25961501P | 2001-01-03 | 2001-01-03 | |
| US60/259,615 | 2001-01-03 | ||
| US26018601P | 2001-01-05 | 2001-01-05 | |
| US60/260,186 | 2001-01-05 | ||
| US26616901P | 2001-02-02 | 2001-02-02 | |
| US60/266,169 | 2001-02-02 | ||
| US26692901P | 2001-02-06 | 2001-02-06 | |
| US60/266,929 | 2001-02-06 | ||
| US27809301P | 2001-03-23 | 2001-03-23 | |
| US60/278,093 | 2001-03-23 | ||
| US28944401P | 2001-05-07 | 2001-05-07 | |
| US60/289,444 | 2001-05-07 | ||
| US29488701P | 2001-05-31 | 2001-05-31 | |
| US60/294,887 | 2001-05-31 | ||
| US29827201P | 2001-06-14 | 2001-06-14 | |
| US60/298,272 | 2001-06-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002556226A Division JP4564714B2 (ja) | 2000-11-27 | 2001-11-27 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014205598A Division JP6124856B2 (ja) | 2000-11-27 | 2014-10-06 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010106028A JP2010106028A (ja) | 2010-05-13 |
| JP2010106028A5 true JP2010106028A5 (enExample) | 2011-03-03 |
| JP5926474B2 JP5926474B2 (ja) | 2016-05-25 |
Family
ID=27583824
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002556226A Expired - Lifetime JP4564714B2 (ja) | 2000-11-27 | 2001-11-27 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
| JP2009271611A Expired - Lifetime JP5926474B2 (ja) | 2000-11-27 | 2009-11-30 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
| JP2014205598A Expired - Lifetime JP6124856B2 (ja) | 2000-11-27 | 2014-10-06 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
| JP2017013054A Expired - Lifetime JP6516778B2 (ja) | 2000-11-27 | 2017-01-27 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002556226A Expired - Lifetime JP4564714B2 (ja) | 2000-11-27 | 2001-11-27 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014205598A Expired - Lifetime JP6124856B2 (ja) | 2000-11-27 | 2014-10-06 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
| JP2017013054A Expired - Lifetime JP6516778B2 (ja) | 2000-11-27 | 2017-01-27 | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7700715B2 (enExample) |
| EP (4) | EP1354196B1 (enExample) |
| JP (4) | JP4564714B2 (enExample) |
| AT (1) | ATE481640T1 (enExample) |
| CA (1) | CA2430060C (enExample) |
| DK (1) | DK2322929T3 (enExample) |
| WO (1) | WO2002056022A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050148101A1 (en) * | 1999-01-23 | 2005-07-07 | Bamdad Cynthia C. | Interaction of colloid-immobilized species with species on non-colloidal structures |
| AU2002216614A1 (en) | 2000-10-03 | 2002-04-15 | Minerva Biotechnologies Corporation | Electronic detection of interaction based on the interruption of flow |
| US7700715B2 (en) * | 2000-11-27 | 2010-04-20 | Minerva Biotechnologies Corporation | Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
| AU2002252459A1 (en) * | 2001-03-22 | 2002-10-08 | Minerva Biotechnologies Corporation | Customized therapeutics and in situ diagnostics |
| EP1425016B1 (en) * | 2001-09-05 | 2010-06-02 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
| US7211561B2 (en) * | 2001-10-12 | 2007-05-01 | Cedars-Sinai Medical Center | Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa) |
| US20060280730A1 (en) * | 2001-10-12 | 2006-12-14 | Cedars-Sinai Medical Center | Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels |
| US20090118605A1 (en) * | 2002-08-30 | 2009-05-07 | Northwestern University | Surface-enhanced raman nanobiosensor |
| US20040180379A1 (en) * | 2002-08-30 | 2004-09-16 | Northwestern University | Surface-enhanced raman nanobiosensor |
| CA2499484A1 (en) * | 2002-09-19 | 2004-04-01 | Medigene Aktiengesellschaft | Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases |
| JP2007531505A (ja) * | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | 癌（ｍｕｃ１）の診断および治療のための技術および組成物 |
| AU2004212004B2 (en) * | 2003-02-13 | 2008-01-10 | Albert Einstein College Of Medicine Of Yeshiva University | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| WO2005007282A2 (en) * | 2003-05-13 | 2005-01-27 | Minerva Biotechnologies Corporation | Storage and use of colloids |
| AU2004248187A1 (en) | 2003-06-12 | 2004-12-23 | University Of Colorado System Technology | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
| US20060173171A1 (en) * | 2003-08-26 | 2006-08-03 | Bamdad Cynthia C | Techniques and compositions for diagnosis and treatment of cancer (muci) |
| DK2363410T3 (en) * | 2003-08-26 | 2018-01-15 | Minerva Biotechnologies Corp | ISOFORMER OF MUC1 |
| US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| CN1984663A (zh) | 2004-03-29 | 2007-06-20 | 南佛罗里达大学 | 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症 |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
| US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
| US20100173864A1 (en) | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| US20080064680A1 (en) * | 2004-09-14 | 2008-03-13 | Bamdad Cynthia C | Methods for Diagnosis and Treatment of Cancer |
| WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
| EP1848804B1 (en) * | 2005-01-28 | 2011-10-05 | Ramot at Tel Aviv University, Ltd. | Anti-muc1 alpha beta antibodies |
| WO2006088798A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation of hypothalamic atp-sensitive potassium channels |
| US8859495B2 (en) | 2005-03-30 | 2014-10-14 | Minerva Biotechnologies Corporation | Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors |
| DK1875244T3 (en) | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
| CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
| US20070224638A1 (en) * | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| US20090075926A1 (en) * | 2006-12-06 | 2009-03-19 | Bamdad Cynthia C | Method for identifying and manipulating cells |
| US20090092603A1 (en) * | 2007-09-25 | 2009-04-09 | Bamdad Cynthia C | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| JP2012504961A (ja) * | 2008-10-06 | 2012-03-01 | ミネルバ バイオテクノロジーズ コーポレーション | Ｍｕｃ１＊抗体 |
| KR20160017117A (ko) | 2008-10-09 | 2016-02-15 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
| MX2011013385A (es) * | 2009-06-11 | 2012-05-29 | Minerva Biotechnologies Corp | Metodos para cultivar celulas madre y celulas progenitoras. |
| EP3065105B1 (en) * | 2009-06-12 | 2020-04-29 | Nikon Corporation | Technique for determining the state of a cell aggregation, image processing program and image processing device using the technique, and method for producing a cell aggregation |
| WO2011013319A1 (ja) * | 2009-07-31 | 2011-02-03 | 株式会社ニコン | 細胞塊の成熟判定手法、この手法を用いた画像処理プログラム及び画像処理装置、並びに細胞塊の製造方法 |
| US8450090B2 (en) | 2009-10-06 | 2013-05-28 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for promoting fatty acid production in plants |
| JP5066615B2 (ja) | 2011-01-31 | 2012-11-07 | 株式会社日立製作所 | フェニルボロン酸基と特異的に結合するオリゴペプチド配列 |
| EP4086338A1 (en) | 2011-03-17 | 2022-11-09 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| EP2768945B1 (en) | 2011-10-17 | 2022-01-05 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| AU2014226650A1 (en) * | 2013-03-08 | 2015-10-01 | Curonz Holdings Company Limited | Neural regeneration peptides and uses therefor |
| CN106132992B (zh) | 2014-01-29 | 2020-08-07 | 达娜-法勃肿瘤研究所公司 | 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体 |
| CN104297442B (zh) * | 2014-11-03 | 2016-08-17 | 天津中医药大学 | 内源性小分子物质在快速检测早期心脏毒性方面的应用 |
| US11123366B1 (en) * | 2014-12-15 | 2021-09-21 | Children's Hospital Of Orange County | Methods, materials, and systems for treating injuries to the central nervous system using light emitting nanoparticles |
| EP3256494A4 (en) | 2015-02-10 | 2018-12-05 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| US10617773B2 (en) | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
| CA3040637C (en) * | 2016-10-17 | 2023-02-28 | Keio University | Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells |
| CA3183682A1 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| CN111875712A (zh) * | 2020-07-31 | 2020-11-03 | 广东昭泰体内生物医药科技有限公司 | 一种增强型靶向muc1的嵌合抗原受体及其应用 |
| CA3248038A1 (en) | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1504A (en) | 1840-03-03 | Mode osi constructing- bedsteads | ||
| US1997A (en) | 1841-03-03 | Improvement in the mode of rendering fabrics water-proof | ||
| US603173A (en) | 1898-04-26 | Motor | ||
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5108933A (en) * | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
| CA2003211A1 (en) * | 1988-11-17 | 1990-05-17 | Pei-Xiang Xing | Monoclonal antibodies |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| IL110464A0 (en) | 1994-07-26 | 1994-10-21 | Univ Ramot | Novel proteins for the diagnosis, imaging, and therapy of human cancer |
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6127393A (en) | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US5767135A (en) * | 1995-12-29 | 1998-06-16 | Fernandez-Pol; Jose Alberto | Antiviral agent |
| FR2746016B1 (fr) * | 1996-03-15 | 1998-04-17 | Combinaisons d'enzymes pour la destruction de cellules proliferatives | |
| US6177393B1 (en) * | 1996-12-12 | 2001-01-23 | The Procter & Gamble Company | Process for making tabletted detergent compositions |
| DE69837754T2 (de) * | 1997-02-18 | 2008-02-07 | Canji, Inc., San Diego | Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung |
| WO2000034783A1 (en) | 1998-12-08 | 2000-06-15 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists of the hdpxu17 receptor |
| CA2360927C (en) * | 1999-01-23 | 2018-03-06 | Minerva Biotechnologies Corporation | Interaction of colloid-immobilized species with species on non-colloidal structures |
| JP5122705B2 (ja) | 1999-01-25 | 2013-01-16 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出 |
| US6421389B1 (en) * | 1999-07-16 | 2002-07-16 | Time Domain Corporation | Baseband signal converter for a wideband impulse radio receiver |
| DE60028996T2 (de) * | 1999-11-12 | 2007-02-08 | The Johns Hopkins University School Of Medicine | Behandlung von krebs durch erhöhung des malonyl-coa-spiegels |
| WO2001057068A1 (en) * | 2000-02-01 | 2001-08-09 | The Austin Research Institute | Mucin-1 derived antigens and their use in immunotherapy |
| WO2002022685A2 (en) * | 2000-09-11 | 2002-03-21 | Kufe Donald W | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| AU2002248909A1 (en) | 2000-11-15 | 2002-05-27 | Minerva Biotechnologies Corporation | Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
| US7700715B2 (en) * | 2000-11-27 | 2010-04-20 | Minerva Biotechnologies Corporation | Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
| WO2002078598A2 (en) | 2001-03-29 | 2002-10-10 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Peptides and antibodies to muc 1 proteins |
| EP1425016B1 (en) | 2001-09-05 | 2010-06-02 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
| CA2459584A1 (en) | 2001-09-05 | 2003-03-13 | Cynthia C. Bamdad | Compositions and use thereof in the treatment of cancer |
| US6716627B2 (en) | 2001-12-20 | 2004-04-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of mucin 1, transmembrane expression |
| EP1497649A4 (en) | 2002-04-22 | 2006-03-22 | Dyax Corp | FOR MUCIN POLYPEPTIDE SPECIFIC ANTIBODIES |
| JP2006502110A (ja) | 2002-07-03 | 2006-01-19 | イミュノジェン・インコーポレーテッド | 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用 |
| JP2007531505A (ja) | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | 癌（ｍｕｃ１）の診断および治療のための技術および組成物 |
| US8510225B2 (en) | 2004-09-01 | 2013-08-13 | Research In Motion Limited | Split channel authenticity queries in multi-party dialog |
-
2001
- 2001-11-27 US US09/996,069 patent/US7700715B2/en active Active
- 2001-11-27 AT AT01989135T patent/ATE481640T1/de not_active IP Right Cessation
- 2001-11-27 CA CA2430060A patent/CA2430060C/en not_active Expired - Lifetime
- 2001-11-27 WO PCT/US2001/044782 patent/WO2002056022A2/en not_active Ceased
- 2001-11-27 JP JP2002556226A patent/JP4564714B2/ja not_active Expired - Lifetime
- 2001-11-27 EP EP01989135A patent/EP1354196B1/en not_active Expired - Lifetime
- 2001-11-27 DK DK10183954.6T patent/DK2322929T3/en active
- 2001-11-27 EP EP10183954.6A patent/EP2322929B1/en not_active Expired - Lifetime
- 2001-11-27 EP EP10184605.3A patent/EP2386859B1/en not_active Expired - Lifetime
- 2001-11-27 EP EP10162600.0A patent/EP2241887B1/en not_active Expired - Lifetime
-
2009
- 2009-11-30 JP JP2009271611A patent/JP5926474B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-27 US US12/695,070 patent/US8344113B2/en not_active Expired - Fee Related
-
2012
- 2012-12-07 US US13/708,790 patent/US20130323755A1/en not_active Abandoned
-
2014
- 2014-10-06 JP JP2014205598A patent/JP6124856B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-27 JP JP2017013054A patent/JP6516778B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534730A5 (enExample) | ||
| EP2414836B1 (en) | Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis | |
| JP2008535494A5 (enExample) | ||
| WO2006105642A1 (en) | Biomarkers for the detection of lung cancer and uses thereof | |
| CN108138238A (zh) | 用于检测胰腺癌的组合物和方法 | |
| EP3963330B1 (en) | Method for the detection of prostate cancer | |
| CN110023326A (zh) | 具有lcst行为的非结构化无重复多肽 | |
| EP2452948B1 (en) | New tumor marker | |
| JP2007533985A5 (enExample) | ||
| AU672808B2 (en) | Method of determining metastatic potential of tumor cells | |
| CN107110848A (zh) | 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法 | |
| CN112162097B (zh) | Gdf1作为评估pd-1单抗治疗效果的生物标志物 | |
| US20150377889A1 (en) | Galectin-3 as a marker for prostate cancer | |
| AU2004300181A1 (en) | A novel method for the detection of cancer biomarkers in cervical specimens | |
| CN104330570A (zh) | 人热休克蛋白gp96在制备筛查肝病的产品中的应用 | |
| CA3103147A1 (en) | Biomarkers for urothelial carcinoma and applications thereof | |
| KR20220141216A (ko) | 유방암 진단을 위한 신규 바이오마커 | |
| US8673309B2 (en) | Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 | |
| JP2013209330A (ja) | 糖尿病合併症マーカーとなり得る新規ｒａｇｅリガンド | |
| CN114729947B (zh) | 检测癌的骨转移的方法和检测试剂 | |
| WO2004108953A1 (ja) | 癌の診断方法、及び癌の罹病性の判定方法 | |
| WO2016172216A1 (en) | Use of soluble crkl compositions as breast cancer biomarkers and predictors of cancer metastasis | |
| JP2000131321A (ja) | 膀胱癌患者の予後診断薬 | |
| WO2015026893A1 (en) | Predictive biomarkers for metabolic syndrome | |
| WO2012038932A2 (en) | Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof |